This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Heed Warning Signs on Intuitive Surgical

NEW YORK (TheStreet) -- Known for its consistent, rock-solid growth, Intuitive Surgical (ISRG - Get Report) has been riding the wave of high expectations over the past couple of years as the stock price has climbed from $100 a share in 2009 to $583 this past January. But as is often the case with high-flyers who consistently escape valuation concerns, there's a point when the music stops.

Unlike other strong med-tech giants like Medtronic (MDT) and Stryker (SYK), shares of Intuitive Surgical have always been expensive. It wasn't hard to figure out when the party was over; Intuitive's investors just didn't want to leave. In January, as the stock peaked, Intuitive posted poor growth results and management followed with a warning in July advising that second-quarter results were going to disappoint.

Even with that warning sending Street estimates lower, the company missed its revenue targets for the July quarter and posted a 3% decline in operating income, about 7% short of estimates.

Three months later, things have not improved. After another earnings disappointment, the stock is down close to 40% from its January high. While I do believe these shares have now reached more rational levels, given that growth in the procedures segment continue to erode, it's anyone's guess as to when the stock will find a bottom.

Although the stock started to decline following the January quarter, shares were up more than 12% in the 30 days leading to the third-quarter report, which suggested optimism among investors. Unlike Stryker and, to a lesser extent, Johnson & Johnson (JNJ), the Street wasn't expecting much for Intuitive this quarter. But with a 7% year-over-year decline in overall revenue, Intuitive went in the opposite direction.

Much of the disappointment was attributable to a 32% decline in systems revenue, which Intuitive claimed was adversely impacted by uncertainty surrounding the implementation of the Affordable Care Act (Obamacare). Now I can't blame this on the company's management since it pointed to Obamacare cited as the reason for the decline. Stryker, and to a lesser extent St. Jude, said the same thing.

But while it's true that hospitals have begun to adjust their spending priorities, I won't ignore that July quarter. Intuitive posted a 6% decline in system revenue. The Affordable Care Act had nothing to do with that. The stock, nonetheless, traded well above $420 a share, which means investors ignored signs of deteriorating growth. Even then Intuitive demonstrated considerable weakness in unit sales, which declined by 5%.

In this quarter, however, unit sales plummeted 35%, led by a 43% decline in U.S. business. The consistent strength of the Instrument and Accessories business, which were up by roughly 10% year-over-year, kept this quarter from complete disaster. Even then, compared to the July quarter, growth in Instruments and Accessories slowed by 8%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ISRG $507.28 -5.40%
AAPL $95.01 1.05%
FB $99.75 -4.15%
GOOG $682.74 -0.12%
TSLA $147.99 -8.99%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs